Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan.

Détails

Ressource 1Télécharger: Haemodynamic Balance in Acute and Advanced Heart Failure.pdf (214.61 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_953CAA204959
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan.
Périodique
Cardiac failure review
Auteur⸱e⸱s
Agostoni P., Farmakis D.T., García-Pinilla J.M., Harjola V.P., Karason K., von Lewinski D., Parissis J., Pollesello P., Pölzl G., Recio-Mayoral A., Reinecke A., Yerly P., Zima E.
ISSN
2057-7540 (Print)
ISSN-L
2057-7540
Statut éditorial
Publié
Date de publication
11/2019
Peer-reviewed
Oui
Volume
5
Numéro
3
Pages
155-161
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
Acute and advanced heart failure are associated with substantial adverse short- and longer-term prognosis. Both conditions necessitate complex treatment choices to restore haemodynamic stability and organ perfusion, relieve congestion, improve symptoms and allow the patient to leave the hospital and achieve an adequate quality of life. Among the available intravenous vasoactive therapies, inotropes constitute an option when an increase in cardiac contractility is needed to reverse a low output state. Within the inotrope category, levosimendan is well suited to the needs of both sets of patients since, in contrast to conventional adrenergic inotropes, it has not been linked in clinical trials or wider clinical usage with increased mortality risk and retains its efficacy in the presence of beta-adrenergic receptor blockade; it is further believed to possess beneficial renal effects. The overall haemodynamic profile and clinical tolerability of levosimendan, combined with its extended duration of action, have encouraged its intermittent use in patients with advanced heart failure. This paper summarises the key messages derived from a series of 12 tutorials held at the Heart Failure 2019 congress organised in Athens, Greece, by the Heart Failure Association of the European Society of Cardiology.
Mots-clé
Acute heart failure, advanced heart failure, cardiorenal syndrome, inodilators, inotropes, levosimendan
Pubmed
Open Access
Oui
Création de la notice
05/12/2019 23:36
Dernière modification de la notice
23/04/2024 7:14
Données d'usage